Skip to main content

Table 1 Characteristics of patients with either salvage cytotoxic chemotherapy (SC) or best supportive care (BSC)

From: Impact of salvage cytotoxic chemotherapy on prognosis in patients with recurrence after radical cystectomy: a multi-institutional retrospective study

Characteristic BSC (n = 48) SC (n = 38) P value
Age, years [median [IQR]) 71 (62–76) 69 (61–75) 0.71
Sex (n [%])
 Male 32 (66.6) 33 (86.8) 0.043
 Female 16 (33.3) 5 (13.2)  
T Stage (n [%])
 ≤ pT2 15 (31.2) 12 (31.6) 0.99
 ≥ pT3 31 (64.6) 25 (65.8)  
 Unknown 2 (4.2) 1 (2.6)  
N Stage (n [%])
 pN0 31 (64.6) 25 (65.8) 0.91
 ≥ pN1 17 (35.4) 13 (34.2)  
Grade (n [%])
 G1/2 13 (27.1) 10 (26.3) 0.99
 G3 31 (64.6) 24 (63.2)  
 Unknown 4 (8.3) 4 (10.5)  
Lymphovascular invasion (n [%])
 Positive 29 (60.4) 25 (65.8) 0.43
 Negative 17 (35.4) 10 (26.3)  
 Unknown 2 (4.2) 3 (7.9)  
Carcinoma in situ (n [%])
 Positive 6 (12.5) 4 (10.5) 0.72
 Negative 40 (83.3) 34 (89.5)  
 Unknown 2 (4.2) 0  
Soft-tissue surgical margin (n [%])
 Positive 6 (12.5) 10 (28.9) 0.10
 Negative 42 (87.5) 28 (71.1)  
Adjuvant chemotherapy (n [%])
 Yes 19 (39.6) 11 (72.7) 0.30
 No 29 (60.4) 27 (27.3)  
Follow-up, months (median [IQR]) 17.1 (9.0–39.3) 27.5 (14.1–40.8) 0.049
  1. IQR interquartile range